and breast cancer. 11 RIT with antibodies recognizing antigens expressed on mesothelioma cells is a potential therapeutic option for malignant mesothelioma.
Podoplanin is a transmembrane sialomucin-like glycoprotein that is highly expressed in several types of cancer, such as brain tumor, 12 squamous cell carcinoma, [13] [14] [15] soft tissue tumors, 16 bladder cancer, 17 and malignant mesothelioma. 18, 19 Podoplanin is associated with epithelial mesenchymal transition, migration, invasion, and metastasis, 20, 21 and its expression correlates with the malignancy grade in brain tumors, lung cancer, and oral cancer. [21] [22] [23] Several anti-podoplanin antibodies inhibit cancer metastasis 24 and cancer progression 12, 19 in mouse tumor models. Therefore, podoplanin is a promising therapeutic target in various cancers, including malignant mesothelioma.
Podoplanin expression is high in cancerous tissues, whereas expression is low in several normal tissues, such as kidney podocytes, 25 alveolar type I cells, 26 lymphatic endothelial cells, 27 basal epidermal keratinocytes, 15 and mesothelial cells. 28 The physiological expression of podoplanin in normal tissues raises some concern about the possible risks of toxicity to these normal tissues induced by podoplanin-targeted anticancer therapy. To address this concern, it is important to select an antibody that recognizes podoplanin expressed on cancer cells only and not on normal cells. We developed a rat anti-podoplanin monoclonal antibody, NZ-1, which has the above-mentioned property, 29 and converted it to a rat-human chimeric antibody named NZ-12. 30 These antibodies recognize podoplanin expressed on the surface of cancer cells, such as brain tumor, lung cancer, and malignant mesothelioma, but not in benign tumor cells or normal organs. 19, 31 Therefore, NZ-12 has potential application for selective antitumor therapy including RIT against malignant mesothelioma.
In the present study, NZ-12 was labeled with radionuclides In-111
and Y-90 to evaluate the in vitro and in vivo properties as a theranostic pair. Y-90 is a pure beta emitter with a high energy level (maximum energy, 2.3 MeV) and an appropriate half-life (64.1 hours) for RIT using IgG. 32 In-111, a gamma emitter with 171 keV and 245 keV and a half-life of 67.4 hours, is used for diagnostic imaging and dosimetry as a surrogate for Y-90. 33, 34 The combination of In-111 and Y-90 is used in clinical practice (eg, Zevalin) 34 in which the 111 Inlabeled anti-CD20 antibody is used for patient selection by SPECT/ CT imaging and the 90 Y-labeled anti-CD20 antibody is used for RIT of non-Hodgkin's lymphoma. In the present study,
111
In-labeled NZ-12 was used for biodistribution and dosimetry studies, and 90 Y-labeled NZ-12 was used to evaluate the antitumor effects in a mesothelioma mouse model.
| MATERIAL S AND ME THODS

| Antibodies
A rat-human chimeric antihuman podoplanin antibody, NZ-12, 30 and a mouse antihuman podoplanin antibody, LpMab-17, 35 were previously developed. As a control, human IgG 1λ was purchased from
Sigma-Aldrich (St Louis, MO, USA). 
| Cell culture
| Radiolabeling of antibody
Antibodies were conjugated with p-SCN-Bn-CHX-A′′-DTPA (CHX-A′′-DTPA; Macrocyclics, Dallas, TX, USA) as described previously. 36 Briefly, the antibody (5 mg/mL) was reacted with an equal molar amount of CHX-A′′-DTPA in 50 mmol/L borate buffer (pH 8. Y labeling, and radiochemical purities were more than 95% after purification with a Sephadex G-50 column. In-labeled NZ-12 or control antibody on ice for 60 minutes. After washing, cell-bound radioactivity was measured using a gamma-counter (ARC-370M; Aloka, Tokyo, Japan 
| Cell binding and competitive inhibition assays
| Tumor model
The animal experimental protocol was approved by the Animal In-labeled IgG 1λ in a total of 20 μg antibody adjusted by adding the appropriate amount of unlabeled antibody. The mice were killed by isoflurane inhalation at 1 hour, and at 1, 2, 4, and 7 days after injection.
Blood, tumor, and organs of interest were sampled and weighed, and the radioactivity was measured using a gamma-counter. The uptake is 
| Histological analysis
H226 tumors were resected from mice on days 1, 3, and 7 after injection and an Envision+ system (Agilent Technologies, Santa Clara, CA, USA).
The nuclei were counterstained with hematoxylin.
| External-beam radiation with X-rays
When H226 tumor volumes reached approximately 80 mm 3 , tumors (n = 5/dose) were irradiated with 0, 25, and 50 Gy of X-rays at a rate of 4.0 Gy/min using a TITAN-320 X-ray generator (Shimadzu, Kyoto, Japan). Other parts of the mouse body were covered with a brass shield to limit unnecessary radiation exposure. Tumor size and body weight were measured at least twice a week for 8 weeks after irradiation, and tumor volume was calculated using the formula mentioned above. When the tumor volume reached greater than 800 mm 3 , the mouse was killed humanely by isoflurane inhalation.
| Statistical analysis
Data were analyzed by ANOVA with Dunnett's multiple comparison tests. Log-rank tests were used to evaluate Kaplan-Meier survival curves based on the endpoint of tumor volume of 500 mm 3 . Data are expressed as means ± standard deviation (SD). The criterion of statistical significance was P < .05.
| RE SULTS
| Podoplanin expression analysis in H226 and 211H cells
Two mesothelioma cell lines, H226 (podoplanin-positive) and 211H
(podoplanin-negative), were used in the present study. 19 To confirm podoplanin expression in these cells, they were immunofluorescently stained with an anti-podoplanin antibody LpMab-17. Strong staining intensity was observed on the cell membranes of H226 cells, but not on 211H (Figure 1 ).
| In vitro characterization of antibody
In cell binding assays with H226 and 211H cells, In-labeled control antibody) shown in Table 1 .
Subsequently, 111
In-labeled NZ-12 tumor uptake significantly increased over time and reached 23.2 ± 0.9% ID/g on day 7, whereas the 111 Inlabeled control antibody showed a slight increase and ranged from 6.5 ± 0.5% to 9.0 ± 1.9% ID/g ( In-labeled control antibody, although there were some statistically significant differences in blood, liver, spleen, and muscle (P < .01 or P < .05, Table 1 ). Based on these results, In contrast, few apoptotic cells, as determined by TUNEL staining, were observed in any of the groups (data not shown).
| Podoplanin expression in human malignant mesothelioma specimens
Human malignant mesothelioma specimens containing three main histological types, epithelioid, sarcomatoid, and mixed, were immunostained with an anti-podoplanin antibody LpMab-17. A positive staining signal was observed both in the cytoplasm and in plasma membranes of tumor cells and tended to be stronger compared with H226 tumors (Figure 6 ). Table 3 provides a summary of the immunohistochemical staining data.
F I G U R E 1 Immunofluorescence staining of H226 (podoplanin-positive) and 211H (podoplanin-negative) cells using anti-podoplanin antibody LpMab-17 (red). The nuclei were counterstained with DAPI (blue)
Positive podoplanin staining on human specimens was found in 90% of all types of malignant mesothelioma specimens: 92% (12/13 cases) of epithelioid-type, 67% (2/3 cases) of sarcomatoid-type, and 100% (3/3 cases) of mixed-type.
| Treatment effects of external-beam radiation with X-rays in nude mice bearing H226 tumors
In mice irradiated with 25 and 50 Gy, H226 tumor volumes increased during the first 14 days and thereafter significantly decreased compared with the control (0 Gy) group (P < .01, Figure 7A ). Tumor reduction was observed until day 28, and tumor volumes gradually 
| D ISCUSS I ON
Malignant mesothelioma is an aggressive tumor with a very poor prognosis. 1 More effective treatments must be developed to improve the prognosis. Malignant mesothelioma shows high expression levels of podoplanin, 19 and the frequency of high podoplanin expression is similar to or higher than that of other mesothelioma-associated antigens such as calretinin, thrombomodulin, cytokeratin 5, WT1, and mesothelin. 28, 38, 39 Therefore, podoplanin is a promising immunological target for diagnosis and therapeutics in malignant mesothelioma.
We previously developed a rat-human chimeric anti-podoplanin antibody, NZ-12, which has high specificity and high binding affinity for podoplanin expressed on mesothelioma cells. 30, 31 In the present study, the potential of radiolabeled NZ-12 as a RIT agent was evaluated in a mesothelioma mouse model.
Immunofluorescence staining analysis of podoplanin expression in mesothelioma cell lines showed that high expression of podoplanin was observed on the membrane of H226 cells, but not on 211H cells, which is consistent with the findings of flow cytometric analysis in a previous study. 19 Thus, H226 as a positive control and 211H as a negative control were considered suitable for the sub- Data are expressed as percentage of injected dose per gram (% ID/g) and as mean ± SD. **P < .01. *P < .05, vs control antibody.
TA B L E difference compared with unirradiated patients. 5 Palliative radiation therapy provides significant pain relief in approximately 50% of malignant mesothelioma patients. 5 In our dosimetry analysis, the ab- Most mesothelioma cells spread into the diaphragm, chest wall, and mediastinum with an irregular shape and are close to critical structures such as the spinal cord, liver, esophagus, heart, and lungs. 42 Therefore, external-beam radiation to mesothelioma in the thorax and mediastinum has substantial technical limitations. 42, 43 The most common toxicities in patients treated with external-beam radiation for thoracic cancer are symptomatic radiation pneumonitis, 44 and the mean dose to the lungs for 20%
risk of radiation pneumonitis is 20 Gy. 44 The estimated absorbed dose in mouse lungs injected with 3.70 MBq of 90 Y-labeled NZ-12 was 14.4 Gy, suggesting a low risk of toxicity to the lungs in patients. The absorbed doses of the other organs are also considered tolerable because these absorbed doses are lower than the tolerance doses of those organs based on the findings of externalbeam radiation studies. 45, 46 This is supported by several previous studies using 90 Y-labeled antibodies, which showed no severe toxicities induced by similar absorbed doses. 10, 47 Therefore, the risk of radiation-induced toxicity from RIT with 90 Y-labeled NZ-12 is expected to be low, although further dosimetry studies in malignant mesothelioma patients are required. that the antitumor effect by RIT is limited, especially in radioresistant tumors, compared with external-beam radiation therapy as a result of lower radiation dose rates of RIT. Similar findings were obtained in our previous RIT studies. 7, 9 H226 is a radioresistant cell line 49 and, thus, the antitumor effect of RIT using 90 Y-labeled NZ-12
for H226 tumors was considered less effective than external-beam radiation therapy at the corresponding doses. However, 90 Y-labeled NZ-12 suppressed tumor growth and, therefore, further efforts as described below, may improve the therapeutic effect to achieve complete remission in malignant mesothelioma patients.
Currently, RIT is applied to hematological malignancies such as lymphoma, but not to solid tumors, because most solid tumors are more radioresistant. 50 To exert the full potential of RIT, radiolabeled antibodies must be specifically delivered in tumoricidal doses to 52, 53 Pemetrexed is recommended as first-line chemotherapy for malignant mesothelioma 5 and is the first candidate as a radiosensitizer with RIT against mesothelioma.
Third, repeated dosing with intact NZ-12 after RIT could enhance the therapeutic effect because NZ-12 is reported to induce potent antibody-dependent cellular cytotoxicity against podoplaninexpressing tumors. 30 NZ-12 is a chimeric antibody and is expected 
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Authors declare no conflicts of interest for this article. F I G U R E 7 Therapeutic efficacy of external-beam radiation with X-rays in nude mice bearing H226 tumors. A, Tumor growth curves after irradiation with X-rays. Data indicate mean and SD (n = 5). **P < .01 and *P < .05 vs 0 Gy. ++ P < .01 and + P < .05, 25 Gy vs 50 Gy. B, Body weight changes after irradiation with X-rays. Data indicate mean and SD (n = 5)
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